Drug May Help Lung Cancer Patients
Posted on: Tuesday, 11 September 2007, 12:00 CDT
By DAMIAN J. TROISE
NEW YORK - ImClone Systems Inc. and Bristol-Myers Squibb Co. claimed Tuesday that the drug Erbitux improved the survival rate of patients with the most common type of lung cancer in a late-stage study. ImClone shares jumped 21 percent.
The drug, already approved to treat colon cancer and head and neck cancer, was given to patients with advanced, non-small cell lung cancer in combination with chemotherapy treatment. The study compared the combination to chemotherapy alone.
The non-small cell type accounts for the overwhelming majority of cases of lung cancer, which is the leading cause of cancer-related death in men and women in the U.S., with 160,000 deaths estimated in 2007.
More detailed results of the study will be presented at a yet-to-be-disclosed medical conference.
Wall Street maintained a positive outlook for the company, with several analysts saying the new late-stage, or Phase III, Erbitux results were unexpected.
Shares of ImClone jumped $7.88 to $45.81 in Tuesday trading and reached a 52-week high of $47.22 earlier in the trading session.
"Phase III Erbitux data in front-line lung cancer are a clear positive," said Morgan Stanley analyst Steven Harr, upgrading the company's stock to "Equal Weight" from "Underweight" in a note to investors. He said the company's earnings could double over the next five years because of the these results.
Still, the drug would face competition from Genentech Inc.'s Avastin, said Citigroup analyst Dr. Yaron Werber.
And in July, ImClone said Erbitux failed a separate late-stage study focusing on lung cancer, in which Erbitux was combined with different chemotherapy drugs. The goal was for approval as an initial treatment for spreading non-small cell lung cancer. The company and Wall Street have since cited the study design for its failure.
"Given recent disappointing data, we do not believe that Erbitux will unseat Genentech's Avastin in this setting," Werber wrote, reaffirming a "Hold" rating, but raising Erbitux sales estimates for 2008 to 2010.
Erbitux is co-promoted in North America with Bristol-Myers.
In August, ImClone named former Johnson & Johnson executive John H. Johnson as its new chief executive. The position had been open since last year, when Carl Icahn won control of the company and became chairman of the board.
Source: Associated Press/AP Online
Related Articles
- Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
- BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
- Researchers Tapped Thomson Reuters Community of Cancer Patients for Studies To Be Reported at American Society of Clinical Oncology Conference
- Pipeline And Commercial Insight Urinary Incontinence Provides An Overview Of Key Marketed Brands Late And Early Stage Pipeline Drugs And Cell Therapies
- Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
- Efficacy Results From a Randomized Phase II Study of Patients With Advanced Lung Cancer Support Continued Study of Concurrent Chemotherapy Plus ERBITUX(R) (Cetuximab); Abstract 7015
- H. Lee Moffitt Cancer Center and Inovio Biomedical Announce Positive Results From Pioneering Human Study of Plasmid DNA Delivery Using Electroporation
- Studies By Texas Cancer Registry Find 18 ZIP Codes With Results Above Average: Area Sees Elevations in Lung Cancer Rates
- Phase I Study of High Dose Weekly ABRAXANE(TM) Published in Journal of Clinical Oncology: Responses Achieved in Patients With Taxol(R) Refractory Ovarian Cancer and Lung Cancer
- Independent Clinical Review of Phase III Trial Shows Erbitux and Radiation Control Spread of Advanced Squamous Cell Cancer of the Head and Neck Better Than Radiation Alone; Primary and Secondary Study Endpoints Met With Statistical Significance
 |
 |
User Comments (0)
RSS Feeds